Browsing: atopic dermatitis

Galderma, a global dermatology company, has received filing acceptances for its breakthrough treatment nemolizumab. The drug is designed to treat prurigo nodularis and moderate-to-severe atopic dermatitis in adolescents and adults. It received regulatory nods from authorities in Australia, Singapore, Switzerland, and the United Kingdom via the Access Consortium framework.

Eczema is a chronic skin condition that affects millions of people worldwide, with a notably higher prevalence in Asia.

Among the many new drug approved for the use of atopic dermatitis or eczema, dupilumab (Dupixent) is one of them. Find out about its evidence here.

The disease burden and current treatment landscape Atopic dermatitis (AD), or eczema, is the most common skin disorder in Singapore…

Disease burden and current treatment landscape Atopic dermatitis (AD) or atopic eczema is a common inflammatory skin condition that affects…

Eczema is a skin condition characterised mainly by itchy, inflamed patches of skin. There are 7 types of eczema, with…

Atopic dermatitis, or commonly known as eczema, is a common chronic inflammatory skin condition characterised by itchy skin accompanied with…